AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
After Pfizer and its German partner BioNTech announcement of an effective clinical trial, US-based biotech firm Moderna has claimed that its experimental vaccine has shown 94.5 per cent effectiveness in the early results from a clinical trial with more than 30,000 participants.
- Moderna CEO Stephane Bancel has stated that the positive first interim analysis has given the clinical validation that the vaccine candidate can prevent Covid-19 disease, including its acute symptoms. The vaccine will not be available outside the US before next year. But around 20 million doses are ready to be shipped within the US before the end of 2020.
- The company had completed the case accrual for the first interim evaluation of the phase 3 COVE study of mRNA-1273 which had seen enrollment of 30,000 participants in the US and was designed in collaboration with the United States Food and Drug Administration and National Institutes of Health.
- It had also announced that Swissmedic had begun a rolling review of its vaccine based on the positive interim analysis of the phase 1 trial and preclinical viral challenge study.
- The initial results of phase 1 study had shown that Moderna’s candidate mRNA-1273 was generally accepted across all age groups and stimulated rapid and strong immune responses against Covid-19.
